Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8506753rdf:typepubmed:Citationlld:pubmed
pubmed-article:8506753lifeskim:mentionsumls-concept:C0026339lld:lifeskim
pubmed-article:8506753lifeskim:mentionsumls-concept:C0021083lld:lifeskim
pubmed-article:8506753lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:8506753lifeskim:mentionsumls-concept:C0026336lld:lifeskim
pubmed-article:8506753lifeskim:mentionsumls-concept:C0021756lld:lifeskim
pubmed-article:8506753lifeskim:mentionsumls-concept:C0011209lld:lifeskim
pubmed-article:8506753lifeskim:mentionsumls-concept:C0439834lld:lifeskim
pubmed-article:8506753pubmed:issue2lld:pubmed
pubmed-article:8506753pubmed:dateCreated1993-7-8lld:pubmed
pubmed-article:8506753pubmed:abstractTextA sustained release system for interleukin-2 (IL-2), and IL-2 mini-pellet (IL-2 mp), was developed by fusing IL-2 into a needle shaped collagen. Serum concentration of IL-2 after a single subcutaneous injection of the IL-2 mp into C57BL/6 mice remained elevated longer than after an injection of aqueous IL-2. IL-2 in the serum became undetectable by 6h after a subcutaneous injection of 1 x 10(6) unit of IL-2 in phosphate-buffered saline (PBS). In contrast, after a single subcutaneous injection of IL-2 mp containing the same amount of IL-2, the concentration of IL-2 increased to its maximum at 6h after injection, then began to decrease gradually. IL-2 was detected even on the third day after a single subcutaneous injection of one IL-2 mp. Augmentation of NK activity and generation of IL-2 activated killer cells were observed in the spleen from day 1--day 3 after a single subcutaneous injection of IL-2 mp into C57BL/6 mice. This activation was not observed following a single subcutaneous injection of the same amount of IL-2 in PBS. Adoptive immunotherapy by a single subcutaneous injection of IL-2 mp followed by intravenous injections of in vitro cultured IL-2 activated killer cells showed better results in decreasing the number of metastases of Lewis lung carcinoma in C57BL/6 mice than immunotherapy using IL-2 solution.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:8506753pubmed:languageenglld:pubmed
pubmed-article:8506753pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8506753pubmed:citationSubsetIMlld:pubmed
pubmed-article:8506753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8506753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8506753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8506753pubmed:statusMEDLINElld:pubmed
pubmed-article:8506753pubmed:monthAprlld:pubmed
pubmed-article:8506753pubmed:issn0386-300Xlld:pubmed
pubmed-article:8506753pubmed:authorpubmed-author:FujiwaraTTlld:pubmed
pubmed-article:8506753pubmed:authorpubmed-author:MatsuokaJJlld:pubmed
pubmed-article:8506753pubmed:authorpubmed-author:OritaKKlld:pubmed
pubmed-article:8506753pubmed:authorpubmed-author:SakagamiKKlld:pubmed
pubmed-article:8506753pubmed:authorpubmed-author:OnodaTTlld:pubmed
pubmed-article:8506753pubmed:authorpubmed-author:GochiAAlld:pubmed
pubmed-article:8506753pubmed:authorpubmed-author:IdaniHHlld:pubmed
pubmed-article:8506753pubmed:issnTypePrintlld:pubmed
pubmed-article:8506753pubmed:volume47lld:pubmed
pubmed-article:8506753pubmed:ownerNLMlld:pubmed
pubmed-article:8506753pubmed:authorsCompleteYlld:pubmed
pubmed-article:8506753pubmed:pagination79-84lld:pubmed
pubmed-article:8506753pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:8506753pubmed:meshHeadingpubmed-meshheading:8506753-...lld:pubmed
pubmed-article:8506753pubmed:meshHeadingpubmed-meshheading:8506753-...lld:pubmed
pubmed-article:8506753pubmed:meshHeadingpubmed-meshheading:8506753-...lld:pubmed
pubmed-article:8506753pubmed:meshHeadingpubmed-meshheading:8506753-...lld:pubmed
pubmed-article:8506753pubmed:meshHeadingpubmed-meshheading:8506753-...lld:pubmed
pubmed-article:8506753pubmed:meshHeadingpubmed-meshheading:8506753-...lld:pubmed
pubmed-article:8506753pubmed:meshHeadingpubmed-meshheading:8506753-...lld:pubmed
pubmed-article:8506753pubmed:meshHeadingpubmed-meshheading:8506753-...lld:pubmed
pubmed-article:8506753pubmed:meshHeadingpubmed-meshheading:8506753-...lld:pubmed
pubmed-article:8506753pubmed:meshHeadingpubmed-meshheading:8506753-...lld:pubmed
pubmed-article:8506753pubmed:meshHeadingpubmed-meshheading:8506753-...lld:pubmed
pubmed-article:8506753pubmed:meshHeadingpubmed-meshheading:8506753-...lld:pubmed
pubmed-article:8506753pubmed:meshHeadingpubmed-meshheading:8506753-...lld:pubmed
pubmed-article:8506753pubmed:year1993lld:pubmed
pubmed-article:8506753pubmed:articleTitleImmunotherapy by a slow delivery system of interleukin-2 in mice models.lld:pubmed
pubmed-article:8506753pubmed:affiliationOkayama Central Hospital, Japan.lld:pubmed
pubmed-article:8506753pubmed:publicationTypeJournal Articlelld:pubmed